What is HC Wainwright’s Forecast for HeartBeam Q2 Earnings?

HeartBeam, Inc. (NASDAQ:BEAT) – Equities research analysts at HC Wainwright issued their Q2 2027 earnings estimates for HeartBeam in a research note issued on Friday, May 22nd. HC Wainwright analyst Y. Chen forecasts that the medical research company will earn ($0.08) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $2.50 target price on the stock. The consensus estimate for HeartBeam’s current full-year earnings is ($0.39) per share.

HeartBeam (NASDAQ:BEAT) last issued its quarterly earnings data on Wednesday, May 13th. The medical research company reported ($0.12) earnings per share for the quarter, beating the consensus estimate of ($0.14) by $0.02.

Several other equities analysts have also weighed in on BEAT. B. Riley Financial assumed coverage on shares of HeartBeam in a research report on Tuesday, March 31st. They issued a “buy” rating and a $4.00 price objective on the stock. Benchmark dropped their price objective on shares of HeartBeam from $8.00 to $5.00 and set a “speculative buy” rating on the stock in a research report on Friday, May 15th. D. Boral Capital lowered shares of HeartBeam from a “buy” rating to a “hold” rating in a research report on Monday, April 20th. Finally, Wall Street Zen raised shares of HeartBeam from a “strong sell” rating to a “sell” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, HeartBeam currently has a consensus rating of “Moderate Buy” and a consensus price target of $4.33.

HeartBeam Price Performance

Shares of BEAT opened at $0.88 on Monday. The firm has a market capitalization of $48.77 million, a PE ratio of -1.57 and a beta of -0.86. The company’s 50-day moving average is $1.05 and its 200-day moving average is $1.48. HeartBeam has a fifty-two week low of $0.54 and a fifty-two week high of $4.00.

Insider Buying and Selling

In other news, Director Mark E. Strome acquired 750,000 shares of HeartBeam stock in a transaction on Thursday, April 16th. The shares were purchased at an average cost of $0.80 per share, for a total transaction of $600,000.00. Following the completion of the purchase, the director directly owned 3,650,000 shares of the company’s stock, valued at approximately $2,920,000. This represents a 25.86% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Richard Ferrari acquired 62,500 shares of HeartBeam stock in a transaction on Thursday, April 16th. The shares were purchased at an average price of $0.80 per share, for a total transaction of $50,000.00. Following the completion of the purchase, the director directly owned 291,636 shares of the company’s stock, valued at approximately $233,308.80. This represents a 27.28% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Over the last three months, insiders have acquired 1,118,750 shares of company stock valued at $895,000. 18.04% of the stock is owned by company insiders.

Institutional Investors Weigh In On HeartBeam

Large investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new stake in HeartBeam during the fourth quarter worth about $70,000. Jane Street Group LLC acquired a new stake in HeartBeam during the fourth quarter worth about $55,000. Insigneo Advisory Services LLC acquired a new stake in HeartBeam during the fourth quarter worth about $74,000. CIBC Private Wealth Group LLC acquired a new stake in HeartBeam during the fourth quarter worth about $26,000. Finally, D Orazio & Associates Inc. grew its stake in HeartBeam by 48.5% during the fourth quarter. D Orazio & Associates Inc. now owns 48,987 shares of the medical research company’s stock worth $118,000 after buying an additional 16,000 shares in the last quarter. 7.77% of the stock is currently owned by institutional investors and hedge funds.

About HeartBeam

BioTelemetry, Inc, a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors.